Crossmark

Authors’ Reply to Comment on “Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide”

Crossref DOI link: https://doi.org/10.1007/s40266-020-00751-4

Published Online: 2020-02-12

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raterman, Hennie G. http://orcid.org/0000-0001-9972-2844
Lems, Willem F.
License Information

Text and Data Mining valid from 2020-02-12

Version of Record valid from 2020-02-12
More Information

Article History

First Online: 12 February 2020

Compliance with Ethical Standards

:

: No funding was received for the preparation of this letter.

: Hennie G. Raterman has received an unrestricted educational grant from UCB, and consulting fees from Amgen, Cellgene and Sanof Genzyme. Willem F. Lems has received a grant from Pfzer, and consulting fees from MSD, Amgen, Lilly, Pfzer and UCB.

Document is current

Any future updates will be listed below